Foshan Kaichuan Pharma

Foshan Kaichuan Pharma is a clinical-stage biopharmaceutical company headquartered in Foshan, China, dedicated to the development of innovative small molecule drugs. The company primarily focuses on oncology and autoimmune diseases, targeting well-validated biological pathways to create best-in-class or first-in-class therapeutics. Its lead candidate, KC-039, is a selective CDK4/6 inhibitor currently undergoing clinical evaluation for the treatment of advanced breast cancer and other solid tumors. Kaichuan Pharma utilizes an efficient R&D engine to advance its pipeline from discovery through early clinical development. The firm is led by a team of industry veterans with extensive experience in global drug discovery and regulatory affairs. By integrating local manufacturing capabilities with global development standards, the company aims to provide affordable and effective treatment options for patients worldwide.